• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Scientific Publications by FDA Staff

  • Print
  • Share
  • E-mail

Search Publications



Starting Date

Ending Date

Order by

Entry Details

AAPS J 2019 Dec 19;22(1):15

Current perspectives on ligand-binding assay practices in the quantification of circulating therapeutic proteins for biosimilar biological product development.

Thway TM, Wang YM, Booth BP, Maxfield K, Huang SM, Zineh I


Bioanalysis in biosimilar biological product development (BPD) plays a critical role in demonstrating pharmacokinetic (PK) similarity across products. The 2018 FDA Bioanalytical Method Validation guidance for industry provides general principles in the development, validation, and conduct of bioanalytical assays. Given that the PK similarity assessment in BPD programs involves two or more non-identical products, there are additional considerations for bioanalytical methods. Here in, we provide our perspectives on the definition of (1) a single bioanalytical method in the context of BPD in supporting a PK similarity study, (2) bioanalytical method comparability during accuracy and precision experiments to determine the potential bias difference prior to assessing other validation parameters, and (3) bioanalytical method validations that support PK similarity assessments.

Category: Journal Article, Editorial
PubMed ID: #31858313 DOI: 10.1208/s12248-019-0397-8
Includes FDA Authors from Scientific Area(s): Drugs
Entry Created: 2019-12-22 Entry Last Modified: 2020-02-23